基于合并疾病的退伍军人接受恩扎卢胺与阿比特龙治疗转移性去势抵抗性前列腺癌的生存分析
回顾性观察研究纳入5822例美国退伍军人,比较恩扎卢胺与阿比特龙初始治疗转移性去势抵抗性前列腺癌的生存。恩扎卢胺组中位总生存24.2个月 vs 阿比特龙组22.1个月(p=0.001);在心血管疾病或糖尿病患者中,恩扎卢胺组中位治疗持续时间11.4 vs 8.6个月(p<0.001),中位总生存23.2 vs 20.5个月(p<0.001)。倾向评分匹配后,恩扎卢胺与阿比特龙相比死亡风险降低(HR 0.90,95%CI 0.84-0.96)。
要点
- 恩扎卢胺组中位总生存24.2个月 vs 阿比特龙组22.1个月(p=0.001)。
- 心血管疾病或糖尿病患者中,恩扎卢胺组中位治疗持续时间11.4 vs 8.6个月(p<0.001)。
- 匹配队列中恩扎卢胺较阿比特龙死亡风险降低(HR 0.90,95%CI 0.84-0.96)。
核心结论
- 伴有心血管疾病或糖尿病的退伍军人接受恩扎卢胺较阿比特龙治疗持续时间更长且总生存更长。
- 作者认为进一步研究ARTA选择可能使转移性去势抵抗性前列腺癌及可能激素敏感性前列腺癌患者获益,尤其是合并疾病患者。
研究设计与样本
- 回顾性观察研究,纳入2014年9月至2017年6月期间开始接受阿比特龙或恩扎卢胺治疗的美国退伍军人转移性去势抵抗性前列腺癌患者。
- 共5822例退伍军人,43.0%初始接受恩扎卢胺,57.0%接受阿比特龙。
- 采用Cox比例风险模型和倾向评分匹配模型评估ARTA与总生存的关联,并调整潜在混杂因素;基于年龄、合并疾病和后续治疗进行敏感性分析。
主要发现
- 恩扎卢胺组较阿比特龙组年龄更大(平均75.8 vs 75.0岁),平均Charlson合并疾病指数更高(4.4 vs 4.1),心血管疾病或糖尿病比例更高(74.2% vs 70.6%)。
- 全体人群中,恩扎卢胺组中位总生存24.2个月 vs 阿比特龙组22.1个月(p=0.001)。
- 心血管疾病或糖尿病患者中,恩扎卢胺组中位治疗持续时间11.4个月 vs 阿比特龙组8.6个月(p<0.001),中位总生存23.2个月 vs 20.5个月(p<0.001)。
- 倾向评分匹配队列中,恩扎卢胺与阿比特龙相比死亡风险降低(HR 0.90,95%CI 0.84-0.96)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comorbid diseases influence patient outcomes, yet little is known about how comorbidities interact with treatments for metastatic castrate-resistant prostate cancer (mCRPC). No head-to-head trials have compared the efficacy of abiraterone and enzalutamide - oral androgen-receptor targeted agents (ARTAs) for mCRPC. In patients with comorbid disease, outcomes with ARTAs may differ due to disparate mechanisms of action, adverse events, and drug interactions. METHODS: Retrospective observational study of US veterans initiating treatment for mCRPC with abiraterone or enzalutamide between September 2014 and June 2017. Treatment duration and overall survival (OS) was compared based on age and comorbid diseases. The association between ARTA and OS was assessed using Cox proportional hazards and propensity-score matched modeling while adjusting for potential confounders. Sensitivity analyses were performed based on patient age, comorbidities, and subsequent treatments for mCRPC. RESULTS: Of 5822 veterans treated for mCRPC, 43.0% initially received enzalutamide and 57.0% abiraterone. Veterans initially treated with enzalutamide versus abiraterone were older (mean 75.8 vs. 75.0 years) with higher mean Charlson comorbidity index (4.4 vs. 4.1), and higher rates of cardiovascular disease or diabetes (74.2% vs. 70.6%). In the entire population, veterans initially treated with enzalutamide had longer median OS compared to those initially treated with abiraterone (24.2 vs. 22.1 months, p = 0.001). In veterans with cardiovascular disease or diabetes, median treatment duration with enzalutamide was longer (11.4 vs. 8.6 months, p < 0.001) with longer median OS compared to abiraterone (23.2 vs. 20.5 months, p < 0.001). In a propensity score matched cohort, enzalutamide was associated with decreased mortality compared to abiraterone (HR 0.90, 95% CI 0.84-0.96). CONCLUSIONS: Veterans with cardiovascular disease or diabetes had longer treatment duration and OS with enzalutamide compared to abiraterone. Further study of ARTA selection may benefit men with metastatic castrate resistant prostate cancer and likely hormone sensitive prostate cancer, especially among patients with comorbid diseases.
引用
- Schoen MW, Carson KR, Eisen SA, et al. Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. Prostate Cancer Prostatic Dis. 2022. PMID: 36104504. doi:10.1038/s41391-022-00588-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。